LPL Financial LLC Cuts Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

LPL Financial LLC reduced its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,637 shares of the medical equipment provider’s stock after selling 1,596 shares during the period. LPL Financial LLC owned 0.07% of Lantheus worth $4,747,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of LNTH. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Lantheus by 3.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider’s stock valued at $1,162,000 after purchasing an additional 400 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in Lantheus by 2.7% during the first quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider’s stock worth $794,000 after purchasing an additional 215 shares in the last quarter. GAMMA Investing LLC lifted its stake in Lantheus by 12,517.1% during the first quarter. GAMMA Investing LLC now owns 128,442 shares of the medical equipment provider’s stock worth $12,536,000 after purchasing an additional 127,424 shares in the last quarter. Cerity Partners LLC lifted its stake in Lantheus by 12.7% during the first quarter. Cerity Partners LLC now owns 11,709 shares of the medical equipment provider’s stock worth $1,143,000 after purchasing an additional 1,323 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in shares of Lantheus by 1,196.4% in the first quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider’s stock valued at $32,817,000 after acquiring an additional 310,301 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the business’s stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the transaction, the director owned 318,650 shares in the company, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 1.50% of the company’s stock.

Lantheus Trading Down 0.2%

Shares of Lantheus stock opened at $53.79 on Thursday. The company has a market capitalization of $3.66 billion, a P/E ratio of 14.31 and a beta of 0.14. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $118.21. The business has a 50 day moving average price of $74.90 and a 200 day moving average price of $86.04.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The company had revenue of $378.05 million for the quarter, compared to analysts’ expectations of $389.69 million. During the same period in the prior year, the firm earned $1.80 earnings per share. The firm’s quarterly revenue was down 4.1% on a year-over-year basis. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on LNTH shares. JMP Securities reduced their price objective on Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 7th. B. Riley dropped their price objective on Lantheus from $122.00 to $109.00 and set a “buy” rating on the stock in a report on Monday, June 23rd. Mizuho decreased their target price on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. William Blair reiterated a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. Finally, Wall Street Zen upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $105.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.